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Abstract 
Objective/Aim: A new group of autoantibodies in Rheumatoid Arthritis (RA), the anti-cyclic 
citrullinated peptide (anti-CCP) antibodies directed to citrulline-containing proteins, which 
are of value for the severity of RA. Up to date, the relationship between anti-CCP antibodies 
and oxidant, anti-oxidant activity in patients with RA has not been elucidated in the previous 
studies. In this study we aimed to investigate the effect of anti-CCP antibodies in the circu-
lation on whole blood, serum and synovial fluid oxidant and anti-oxidant activity in patients 
with RA. Materials and Methods: RA patients with anti-CCP (+) (n=25) and anti-CCP (-) 
(n=24) were recruited into the study. All patients had a positive rheumatoid factor (RF). The 
patients who were under treatment with only non-steroidal antiinflammatory drugs (NSAID) 
at the study time included in the study. Catalase (CAT), Glutathione peroxidase (GSHPx), 
Myeloperoxidase (MPO) activities and the levels of Malondialdehyde (MDA) were measured 
in whole blood, serum and synovial fluid in both groups. Results: There were no significant 
differences in terms of the mean whole blood and serum antioxidative activity (CAT, GSHpx) 
and the mean blood and serum MDA and MPO values (oxidative activity), between the pa-
tients with anti-CCP(+) and those with anti-CCP(-). There was increased synovial oxidant 
activity (MDA and MPO levels) (p<0.05) in anti-CCP(+) RA patients with or without ESR 
negativity when compared with anti-CCP(-) RA patients. There was positive correlation 
between anti-CCP antibody levels and synovial MDA and MPO levels (r=0.435, p<0.05, 
r=0.563, p<0.05 respectively) in anti-CCP (+) group. Conclusions: In conclusion, anti-CCP 
antibody positivity seems to be associated with increased synovial fluid oxidant activity (in-
creased MDA and MPO levels) in patients with RA. These conclusions need to be validated in 
a larger controlled study population. 
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Introduction 
Rheumatoid Arthritis (RA) is a chronic, inflam-
matory,  autoimmune,  systemic  disease,  in  which 
various  joints  in  the  body  are  inflamed,  leading  to 
swelling, pain, stiffness, and the possible loss of func-
tion.  Pathologically,  synovial  proliferation  and  de-
struction of the articular cartilage and bone occur in 
the  disease  course  [1].  Free  radical/reactive  oxygen 




atom  or a molecule that  has one  or  more unpaired 
electrons in its valance shell which makes it unstable, 
short lived and highly reactive, therefore, for gaining 
stability, it attacks the nearest stable molecule “steal-
ing” its electron. When the attacked molecule looses 
its electron, it becomes a free radical itself, beginning a 
chain  reaction  cascade  resulting  in  disruption  of  a 
living cell [2]. It is well established now that free rad-
icals/ROS play an important role in chronic inflam-
mation [2]. Oxygen metabolism has an important role 
in  the  pathogenesis  of  RA.  Free  radicals/ROS  pro-
duced in the course of cellular oxidative phosphory-
lation and repetitive cycles of hypoxia and reoxygen-
ation,  along  with  oxidants  produced  by  phagocytic 
cells  such  as  macrophages  and  neutrophils,  lead  to 
chronic oxidative stress in the RA synovial microen-
vironment and the other tissues [3].  
Increased oxidative stress in synovial tissue and 
synovial fluid may be associated with increased dis-
ease activity, tissue demage and bone erosions in RA. 
It has been shown that, especially in RA, monocytes 
produce 2.7 times more oxygen radicals than controls 
[4].  Clinical  evidence  has  also  suggested  oxidative 
stress is elevated in RA patients. Plasma malondial-
dehyde  (MDA),  a  degradation  product  of  lipid  pe-
roxidation, level was significantly higher in the syno-
vial fluid and serum of RA patients than that of con-
trol  subjects  [5,6].  Epidemiologic  studies  have  also 
shown an inverse association between dietary intake 
of antioxidants and RA incidence [7], and inverse as-
sociations between antioxidant levels and inflamma-
tion have been found [8,9]. 
A new group of autoantibodies that have gener-
ated particular interest are the anti-cyclic citrullinated 
peptide  (anti-CCP)  antibodies  directed  to  citrul-
line-containing proteins, which appear to be of value 
for the diagnosis and especially severity of RA [10], 
and  also  closely  correlated  to  inflammatory  disease 
activity (Disease Activity Score-DAS28) scores and the 
presence,  development,  and  extent  of  joint  erosions 
[1].  Anti-CCP  antibodies  are  actively  produced  or 
enriched at the site of inflammation (joints and syno-
vial tissue) and may play an active role in the patho-
genesis of Anti-CCP positive RA by enhancing oxida-
tive stress in rheumatoid joint [11]. Indeed, high titers 
of anti-CCP antibodies have been associated with an 
erosive disease course and outcome in RA [1,10,12]. 
Anti-CCP antibodies can also induce or enhance ar-
thritis and tisuue demage in the mouse [13]. 
The  effects  of  anti-CCP  antibodies  on  whole 
blood,  serum  and  synovial  fluid  oxidant  and  an-
ti-oxidant activity in patients with RA has not been 
elucidated in the previous studies. In this study we 
aimed to investigate the effect of anti-CCP antibodies 
in the circulation on whole blood, serum and synovial 
fluid  oxidant  and  anti-oxidant  capacity  in  patients 
with RA. 
Methods 
RA  patients  with  anti-CCP  (+)  (n=25)  and  an-
ti-CCP  (-) (n=24)  were recruited  into  the  study.  All 
patients  fulfilled  the  revised  American  College  of 
Rheumatology (ACR) criteria for RA [14]. All patients 
had  a  positive  rheumatoid  factor  (RF).  RF  negative 
patients were excluded from the study. Consent for all 
procedures  was  obtained  from  each  individual  and 
from the university research ethics committee. Blood 
and synovial fluid samples were taken from the pa-
tients. The patients were  chosen for the  study after 
having a preliminary evaluation consisting of a brief 
medical  history,  smoking  and  alcohol  habits  and 
physical examinations. Inflammatory disease activity 
was defined as a Disease Activity Score (DAS 28). All 
patients evaluated in terms of RF, CRP, ESR, and an-
ti-CCP2 status. DAS 28 scores, tender joint count, du-
ration of morning stiffness. Patients with any history 
of  chronic  diseases  such  as  liver  diseases,  diabetes 
mellitus,  respiratory  disorders,  cardiovascular  dis-
eases and alchohol usage and smoking were not in-
cluded  in  the  study.  The  patients  who  were  under 
treatment  with  only  NSAID  at  the  study  time  in-
cluded in the study. Those who had been receiving 
corticosteroid agents and under treatment with dis-
ease modifying anti-rheumatic drugs and anti-TNF or 
other biological agents for at least 3 months before the 
study date were excluded from this study.  
Determination of anti-CCP2 antibody 
Anti–CCP2 antibody was determined by ELISA 
(Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, 
The Netherlands) which was performed according to 
the  manufacturer’s  instructions  (sensitivity  74%, 
specificity 97–99%). 
Determination of oxidant and antioxidant activi-
ties in whole blood, serum and synovial fluid 
Totally 5 ml sample of venous blood and 3 ml 
sample of synovial fluid from knee was taken from 
each individual in the morning, before breakfast. 2 ml 
of them was taken in tube with EDTA, and the rest in 
biochemical tube. Samples were kept in a cool box at 
+4 °C until they were transferred immediately to the 
laboratory, where they were immediately centrifuged. 
Serum was stored at -20 °C until analysis. The serum 
samples were obtained by centrifuging blood samples 
at 3000 rpm for 15 min at +4 °C. Whole blood samples 
and  synovial  fluid  were  hemolyzed  with  distillated 




min at +4 °C. The clear upper supernatant fluid was 
taken.  Catalase  (CAT),  Glutathione  peroxidase 
(GSHPx), Myeloperoxidase (MPO) activities and the 
levels of Malondialdehyde (MDA) were measured in 
whole blood, serum and synovial fluid.  
Malondialdehyde (MDA) analysis  
Lipid peroxidation (MDA) levels of whole blood, 
serum  and  synovial  fluid  were  measured  with  the 
thiobarbituric acid reaction by the method of Placer et 
al. [15]. The quantification of thiobarbituric acid reac-
tive  substances  was  determined  by  comparing  the 
absorption to the standard curve of MDA equivalents 
generated by acid catalyzed hydrolysis of 1,1,3,3 tet-
ramethoxypropane.  The  optical  density  was  meas-
ured  at  532  nm  for  samples  MDA  level  (Shimadzu 
UV-VIS  Spectrophotometer  UV1201).  The  level  of 
MDA was expressed as nmol/ml sample.  
Catalase (CAT) analysis  
CAT  (EC  1.11.1.6)  activity  was  determined  by 
the method of Aebi [16]. The principle of the assay is 
based on the determination of the rate constant (s−1, k) 
of the H2O2 decomposition rate at 240 nm. Activities 
were expressed as k ml−1 sample.  
Glutathione peroxidase (GSH-Px) analysis  
GSH-Px activity of the whole blood, serum and 
synovial fluid samples was measured spectrophoto-
metrically  (Shimadzu  2R/UV–Vis)  at  378C  and  412 
nm according to Matkovics et al [17]. GSH-Px activity 
in samples was expressed as units (U/ml) of GSH-Px 
activity.  
Myeloperoxidase (MPO) analysis 
MPO  activity  was  measured  according  to  the 
modified method of Bradley et al [18]. MPO activity in 
the supernatant was determined by adding 100 µl of 
the  supernatant  to  1.9  ml  of  10  mmol/l  phosphate 
buffer (pH 6.0) and 1ml of 1.5 mmol/l o-dianisidine 
hydrochloride  containing  0.0005%  (w/v)  hydrogen 
peroxide.  The  changes  in  absorbance  at  450  nm  of 
each sample were recorded on a UV-Vis spectropho-
tometer. MPO activity in samples was expressed as 
units (U/ml) of MPO activity.  
Statistical analysis 
Results  were  expressed  as  mean  and  standard 
deviation  (SD).  Statistical  analysis  was  carried  out 
using the SPSS program (version 13.0 software, SPSS 
Inc.  Chicago,  Illinois,  USA).  For  the  comparison  of 
groups,  independent  student  t  test  and 
Mann-Whitney U test were used. P values of less than 
0.05  were  regarded  as  significant.  Spearman  rank 
correlation analysis was applied to assess correlation. 
Results 
The RA subjects with anti-CCP (+) were 25 indi-
viduals  (18  females,  7  males),  aged  39  to  63  years 
(mean age 54.4 ± 9.6). The mean anti-CCP antibody 
levels  was  96.72±  61.07  U/ml  (mean±SD)  in  an-
ti-CCP(+) group. The RA patients without anti-CCP 
consisted of 24 individuals (19 females, 5 males), aged 
42 to 62 years (mean age 56.2 ± 11.2). As shown in 
Table  1,  RA  patients  with  anti-CCP(+)  had  signifi-
cantly higher DAS 28 scores, tender joint count and 
morning stiffness time (p<0.01) than that of those with 
anti-CCP(-). Other demographic, clinical and labora-
tory characteristics did not show statistically signifi-
cant differences between groups. 
There were no significant differences in terms of 
the mean whole blood and serum antioxidative activ-
ity  (CAT,  GSHpx)  and  the  mean  blood  and  serum 
MDA and MPO values (oxidative activity), between 
the  patients  with  anti-CCP(+)  and  those  with  an-
ti-CCP(-) (Table 2). 
 
In the synovial fluid, there was increased syno-
vial oxidant activity (MPO and MDA levels) (p<0.05) 
in anti-CCP(+) patients with RA when compared with 
anti-CCP(-) RA patients (Table 3). There were no sig-
nificant differences in terms of the mean synovial an-
tioxidative activity (CAT, GSHpx) values between the 
patients with anti-CCP(+) and those with anti-CCP(-). 
Spearman’s correlation showed positive correla-
tions  between  serum  anti-CCP  antibody  levels  and 
synovial  MDA  and  MPO  levels  (r=0.435,  p<0.05, 
r=0.563,  p<0.05  respectively)  in  anti-CCP  (+)  group 
(Figure 1). But there were no significant correlations 
between anti-CCP antibody levels and  whole blood 
and  serum  MPO,  MDA, GSHpx  and  CAT  levels  as 
well as synovial GSHpx and CAT levels in anti-CCP 
(+) group. 
Because  of  oxygen  metabolism  (Free  radi-
cal/reactive  oxygen  species)  is  related  with  inflam-
mation, to reveal the relationship between anti-CCP 
and synovial fluid oxygen metabolism we examined 
oxidative status in ESR negative patients. Although, 
there  is  no  clear  rational  cut  off  for  activity  (or  for 
normality) of ESR in RA, the usual clinical trial activ-
ity cutpoints for ESR are 28–30 mm/h [19]. For that 
reason, a cut off value for ESR negativity was assessed 
as 28 mm/h. Ten patients in anti-CCP(+) group and 
12 patients in anti-CCP(-) group were ESR negative. 
While only ESR negative patients compared between 
the  groups,  there  were  no  significant  differences  in 
terms of serum oxidant levels and antioxidant activity 
(p>0.05). On the other hand, there were still signifi-




ovial oxidant levels (MDA and MPO levels) (p<0.05) 
(Table 4). Moreover, there was still a significant posi-
tive correlation between serum anti-CCP and synovial 
fluid MPO levels  [r=0.693, p<0.05- but not synovial 
fluid MDA levels (r=0.480, p>0.05)] in ESR negative 
patients of anti CCP(+) group (Figure 2). 
 
Table 1 Demographic and some clinical and laboratory characteristics of RA patients with anti-CCP (+) and anti-CCP (-). 





Age (years)  54.4 ± 9.6   56.2 ± 11.2  NS 
Gender female/male  18/7  19/5  NS 
Body mass index (BMI) kg/m2  24.5±1.4  25.3±1.9  NS 
Duration of disease (years)  9.6 ± 6.3   8.1 ± 7.5  NS 
Morning stiffness (minutes)  34.7 ± 33.6   17.8 ± 23.5  0.004* 
Tender joint count  5.7 ± 5.2  2.8± 3.3  0.007* 
DAS 28 scores  4.1± 1.8  3.4± 1.3  0.006* 
ESR mm/hr   37.9 ± 26.8  33.6 ± 21.3  NS 
CRP mg/L   34.3 ± 23.8  31.4 ± 29.8  NS 
 *p<0.01, NS: Nonsignificant 
 
Table 2 Serum and whole blood oxidant activity; MDA and MPO levels, and antioxidant activity; CAT and GSH-Px levels in 
anti-CCP(+) and anti-CCP(-) patients with RA.  
  Anti-CCP  N  Mean  Std. Deviation   p value 
Serum GSHpx (U/ml)   negative  24   0.47   0.25   0.622 
positive  25   0.48   0.19   
Whole Blood GSHpx (U/ml)   negative  24  14.10  6.67   0.614 
positive  25  15.63  4.39   
Serum CAT  
(k ml−1)  
negative  24   0.11   0.03   0.267 
positive  25   0.13   0.01   
Whole Blood CAT (k ml−1)  negative  24  114.23  21.15   0.322 
positive  25  112.21  20.66   
Serum MDA (nmol/ml)  negative  24  3.34   0.15   0.141  
positive  25  3.52   0.32   
Whole Blood MDA (nmol/ml) negative  24  50.39  7.29   0.233 
positive  25  53.63  7.50   
Serum MPO (U/ml)   negative  24   0.64   0,28  0.487 
positive  25   0.62   0,20   
Whole Blood MPO (U/ml)  negative  24  67.44  25.04   0.218 
positive  25   71.13   20.93   
 
 
Table 3 Synovial fluid oxidant activity; MDA and MPO levels, and antioxidant activity; CAT and GSH-Px levels in an-
ti-CCP(+) and anti-CCP(-) patients with RA. 
 
 
Anti-CCP antibody  N  Mean  Std. Deviation  p value 
Synovial GSHpx (U/ml)  negative  24   0.072   0.027   0.432 
positive  25   0.074   0.032   
Synovial CAT (k ml−1)  negative  24   0.156   0.088   0.324 
positive  25   0.145   0.086   
Synovial MDA 
(nmol/ml) 
negative  24  2.852   0.509   0.021* 
positive  25  4.592   0.780   
Synovial MPO (U/ml)  negative  24  3.134  2.125   0.037* 
positive  25  4.783  2.654   
*p<0.05 
 








Anti-CCP antibody  N  Mean  Std. Deviation  p value 
Synovial MDA 
(nmol/ml) 
negative  12  2.912   0.712   0.048* 
positive  10  4.314   0.780   
Synovial MPO (U/ml)  negative  12  3.303  1.865   0.032* 




Fig 1. There were significant correlations between the antibodies against citrullinated peptide (CCP-AB) levels and synovial 







Fig 2. There was significant correlation between the antibodies against citrullinated peptide (CCP-AB) levels and synovial 
fluid MPO levels [(r=0.693, p<0.05, but not synovial fluid MDA levels, r=0.480, p>0.05)] of the subjects whom ESR was 
below 28 mm/h in anti-CCP(+) group.  
 
Discussion 
In the current study, we evaluated the relation-
ship between serum anti-CCP antibody positivity and 
whole blood, serum and synovial fluid oxidant as well 
as antioxidant capacity in patients with RA, and we 
found  positive  correlations between anti-CCP an-




dant activity (increased MDA and MPO levels) in the 
synovial fluids of patients with RA. But no relation-
ship between anti-CCP antibody existence and blood 
and serum oxidant activity and antioxidant defense 
system were found. Also we found no significant dif-
ferences in terms of the mean synovial antioxidative 
activity  (CAT,  GSHpx)  values  between  anti-CCP(+) 
and anti-CCP(-) RA patients. 
RA  patients  positive  for  anti-CCP  represent  a 
subset of RA that is characterized by an aggressive 
disease course, including bone erosion [10,20]. Indeed, 
Anti-CCP is strongly associated with both prevalent 
tissue erosions and the development of erosions in RA 
joint tissues [1]. A high disease specificity of anti-CCP 
coupled with reasonable sensitivity and high predic-
tive value for RA progression and radiological dam-
age suggest that anti-CCP may play an important role 
in RA pathogenesis. Anti-CCP antibodies may also be 
related  increased  oxidative  activity  in  RA  patients. 
Anti-CCP  antibodies  are  directed  against  antigens 
containing the nonstandard amino acid citrulline, for 
example,  citrullinated  fibrin,  which  is  found  in  the 
rheumatoid joint [21]. The citrulline moiety, which is 
the essential part of the antigenic determinant in these 
antigens, is post-translationally generated by peptidyl 
arginine  deiminases  (PAD)  [22].  Some  reults  in  the 
literature also suggest that anti-CCP may be related 
increased  oxidative  activity  in  RA  patients.  For  ex-
ample, TNF-alpha inhibitors act as a regulator against 
pentosidine formation, oxidative DNA damage, and 
lipid peroxidation and is associated with a decrease in 
serum  levels  of  oxidative  stress  markers,  and  also 
anti-CCP antibody levels in RA patients [23,24].  
Although the pathophysiological basis of RA is 
not yet fully understood, free radicals/ROS have been 
implicated in its pathogenesis [25], and several studies 
have  demonstrated  increased  oxidative  enzyme  ac-
tivity along with decreased, increased or unchanged 
antioxidant  levels  in  RA  sera  and  synovial  fluids 
[26-28].  Our  study  may  also  explain  these  different 
results in RA patients, because previous studies did 
not  allocate  the  subjects  according  to  the  anti-CCP 
antibody  positivity.  Antioxidants  and  oxidative  en-
zymes  have  been  shown  to  ameliorate  arthritis  in 
animal models [29]. Studies of RA synovial fluid and 
tissue  have  also  demonstrated  oxidative  damage  to 
hyaluronic  acid,  low-density-lipid  proteins  (LDL), 
proteins,  cartilage,  extracellular  collagen,  and  intra-
cellular DNA [30,31]. These are highly reactive tran-
sient chemical species (nitric oxide (NO), superoxide 
anion, hydrogen peroxide (H2O2), and hydroxyl rad-
ical  (OHS),  with  the  potential  to  initiate  cellular 
damage  in  joint  tissues  especially  in  RA.  They  are 
formed by phagocyte activation during inflammation.  
The current study showed no relationship be-
tween anti-CCP antibody existence and blood and 
serum  antioxidant  defense  system  (CAT,  GSHpx). 
There were no statistically differences in both groups 
(anti-CCP(+) and anti-CCP(-)) in terms of blood and 
serum oxidant activity and antioxidant defense sys-
tem.  Cells  and  tissues  are  protected  from 
ROS-induced  damage  by  a  variety  of  endogenous 
ROS  scavenging  proteins,  enzymes,  and  chemical 
compounds. If these ROS are not scavenged by anti-
oxidant  mechanisms,  these  species  may  lead  to 
widespread lipid, protein, and DNA damage in cells 
and tissues of patients with RA [5]. Several antioxi-
dant  systems  such  as  superoxide  dismutase  (SOD), 
CAT,  and  GSH-Px  dependent  mechanisms  which 
have different activities have been reported. SOD, the 
first  line  of  defense  against  ROS,  catalyzes  the  dis-
mutation of the superoxide anion into hydrogen per-
oxide.  Hydrogen  peroxide  can  then  be  transformed 
into H2O and O2 by CAT. GSH-Px is a selenoprotein 
which reduces lipidic or nonlipidic hydroperoxides as 
well as H2O2 while oxidizing glutathione [32]. 
In  this  study,  we  found  a  positive  correlation 
between anti-CCP antibody levels and increased 
oxidant  (MDA  and  MPO)  activity  in the synovial 
fluid of patients with RA. One of the end-products 
of lipid peroxidation (LPO) damage is MDA which 
was  found  to  be  increased  because  of  the  reduced 
antioxidant defense system in patients with RA. Ele-
vated levels of this end-product have been reported in 
the serum, plasma and synovial fluid in patients with 
RA [29]. But no change in plasma MDA levels has also 
been reported [33]. The decreased plasma total anti-
oxidant  capacity  (TAC)  levels  and  increased  MDA 
and erithrocyte sedimentation rate (ESR) in patients 
with RA were reported in the previous studies and 
may be related to the severity of RA [26-28,34]. MPO 
is a heme-containing peroxidase. Enzymatically active 
MPO, together with hydrogen peroxide and chloride, 
produces  the  powerful  oxidant  hypochlorous  acid 
and  is  a  key  contributor  to  the  oxygen-dependent 
tissue damage in chronic inflammatory diseases [35]. 
Our study showed a relationship between increased 
synovial fluid MPO and anti-CCP antibody positivity.  
A previous study revealed that the levels of an-
ti–CCP antibodies are higher in synovial fluid than in 
serum [36]. It was also demonstrated that antibodies 
to the citrullinated antigens were produced and en-
riched in the joints of the RA patients [11]. This may 
explain why synovial fluid oxidative stress markers 
(MPO and MDA levels) were increased while serum 
oxidative stress markers were normal in this study. If 




measured,  it  could  have  been  provide  more  infor-
mation in this study. But, because a limited number 
of our anti-CCP antibody kit, we thought to detect 
anti-CCP antibody levels in serum would be sufficient 
for the purpose of this study. 
Limitations of the current study; i. Small sample 
size  which  leads  to  lower  statistical  power.  ii.  an-
ti-CCP antibodies were not detected in synovial fluid 
and  iii.  DAS-28  scores,  morning  stiffness  time  and 
tender joint count at the assessment time were higher 
in anti-CCP(+) group. 
In  conclusion;  In  the  current  study,  we  found 
relationships  between  anti-CCP  antibody  existence 
and increased MPO and MDA levels (oxidant activity) 
in the synovial fluid of patients with RA. But there 
were  no  relationships  between  anti-CCP  antibody 
existence and whole blood and serum oxidant status 
and antioxidant defense system. Anti-CCP antibody 
positivity seems to be associated with increased syn-
ovial fluid oxidant activity (increased MDA and MPO 
levels) in patients with RA. And this increased oxida-
tive activity in synovial fluid may be one of the re-
sponsible factors for accelerated bone erosions seen in 
anti-CCP  positive  RA  patients.  These  conclusions 
need to be validated in a larger controlled study pop-
ulation. 
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